Join to View Full Profile
4460 Bissonnet StSte 200Bellaire, TX 77401
Phone+1 713-524-3434
Fax+1 713-524-3220
Dr. Wykoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Board Certified by the American Board of Ophthalmology. Partner at Retina Consultants of Houston & Clinical Assistant professor at Weill Cornell Medical College, Houston Methodist Hospital. Research interests: angiogenesis & exudative retinal diseases as well as vitreoretinal surgery topics including trauma, retinal detachments, diabetic retinopthay, & macular holes. Principle investigator on numerous clinical trials including novel approaches to treating AMD, RVO and diabetic retinopathy. Member of the Macula Society, ASRS, AAO, and ARVO.
Education & Training
B Palmer Eye Institute - A B Leach EyeChief Residency, Chief Resident & Co-Director of Ocular Trauma, 2010 - 2011
University of Miami Hospital and ClinicsFellowship, Surgical Retina and Vitreous, 2009 - 2011
University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2006 - 2009
Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 2005 - 2006
Harvard Medical SchoolClass of 2005
Certifications & Licensure
TX State Medical License 2011 - 2026
FL State Medical License 2009 - 2015
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Start of enrollment: 2012 Oct 01
- Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab Start of enrollment: 2012 Dec 01
- A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Spectral-domain OCT characteristics of intraretinal hyper-reflective foci associated with age-related macular degeneration and diabetic retinopathy.Maryam Ashrafkhorasani, Abbas Habibi, Muneeswar Gupta Nittala, Mehdi Yaseri, Mehdi Emamverdi
Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie. 2025-04-01 - Morphologic Stages of Full-Thickness Macular Hole on Spectral-Domain OCT.Aurora Pecaku, Isabela Martins Melo, Jessica A Cao, Shiva Sabour, Sumana C Naidu
Ophthalmology. Retina. 2025-04-01 - Clinical Outcomes in nAMD with Aflibercept 8 mg in the Phase 2 CANDELA Study.Jordana G Fein, Priya S Vakharia, A Paul Chous, Rutvi Desai, Fabiana Q Silva
Ophthalmology. Retina. 2025-04-01
Journal Articles
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyCharles C Wykoff, Srinivas R Sadda, JAMA Ophthalmology
- Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging with Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLee M Jampol, Lloyd Paul Aiello, Jennifer K Sun, Szilard Kiss, Charles C Wykoff, Neil M Bressler, JAMA
Authored Content
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
Press Mentions
FDA Approves Neurotech’s ENCELTO, First for Macular Telangiectasia Type 2March 20th, 2025- Neurotech’s ENCELTO™ (Revakinagene Taroretcel-Lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)March 6th, 2025
- Opthea Treats Final Patient in Phase 3 COAST Trial for Wet AMDFebruary 18th, 2025
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
